REGENXBIO INC (RGNX)
Health Care · Biotechnology - Gene Therapy · NASDAQ
Clinical-stage gene therapy company using proprietary NAV vectors to deliver functional genes for rare genetic and retinal disorders through partnerships with major pharma.
What REGENXBIO INC does
RegenxBio Inc. is a clinical-stage gene therapy company developing treatments for inherited retinal diseases, hemophilia B, and other genetic disorders. The company employs adeno-associated virus (AAV) vectors as its core technology platform to deliver therapeutic genes to target tissues. Key programs include collaborations with AbbVie for surabgene lomparvovec (ABBV-RGX-314) and with Nippon Shinyaku for RGX-121 and RGX-111, alongside an internal pipeline of investigational therapies in clinical and preclinical development.
Themes: Gene therapy / AAV-based treatments, Inherited retinal diseases, Lysosomal storage disorders, Hemophilia B, Genetic disorders / rare diseases
Fundamentals
- Price$10.72 as of 2026-08-21 close
- Market cap$708M as of 2026-08-21
- 1-year return+32.2% 2025-08-21 close $8.11 → 2026-08-21 close $10.72
- P/En/a negative earnings
- Net margin-112.6% as of 2026-08-24
- Gross margin+86.4% as of 2026-08-24
- ROE-220.1% as of 2026-08-24
- Debt / equity2.53 as of 2026-08-24
- Revenue growth (YoY)+12.0% as of 2026-08-24
- Revenue CAGR (3y)+14.8% SEC XBRL
- Beta1.10 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How RGNX compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How REGENXBIO INC looks technically
REGENXBIO INC (RGNX) is trading 2.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 3 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago. It is 33.8% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 2.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +2.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $10.75 | $10.75 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $10.50 | $10.50 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 11.5. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 3 trading days ago — a "golden cross", a bullish long-term signal | 3 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 2.1% above | +2.1% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend) | 13.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30) | 49.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($9.87 to $12.08) — its "stochastic" reading is 38 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 38.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $16.19 | $16.19 |
|---|---|---|
| From the 52-week high | it is 33.8% below its 52-week high (its highest price of the past year) | -33.8% |
| Above the 52-week low | it is 96.3% above its 52-week low (its lowest price of the past year) | +96.3% |
| Below the 52-week high | it is 33.8% below its highest point of the past year | 33.8% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 32 trading days ago | 32 sessions |
| All-time high | its highest closing price on record is $85.10 (set on 2018-07-10) | $85.10 |
| Given back of the 52-week move | over the past year its closes ranged ($5.65 to $15.98), and it has recovered around half of its fall from last year’s high — 49% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $12.03 to $12.36. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 49.1% |
| From the all-time high | it is 87.4% below its all-time high | -87.4% |
| Nearest price level | it is trading 0.7% below a resistance level at $10.79 — a price it turned at twice since 2025-11-07, most recently on 2026-03-10. Since 2024-08-21 it has 12 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.7% |
| All-time low | its lowest closing price on record is $5.04 (set on 2025-04-09) | $5.04 |
| Above the all-time low | it is 112.9% above its all-time low | +112.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 79% of it) | 21st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.8032 between its high and its low — about 7.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.8032 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $9.30 and $11.81 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $9.30 – $10.56 – $11.81 |
| Typical daily range (% of price) | its price moves about 7.5% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.5% |
| Stretch from the 200-day average | it is trading 0.3 daily ranges above its 200-day average price (2.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.67× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 8.1% since the prior reading | +8.1% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.09 toward sell |
Candlestick patterns
1
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.7% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.7% |
|---|---|---|
| Open gap | it gapped 2.8% below the previous close 29 sessions ago and has not traded back through the level it left behind at 13.95 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.8% |
| Gap filled | a 3.9% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -10.82% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 1.3 percentage points (the stock gained 3.7% while the market gained 2.3%) | +1.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 55.7 percentage points (the stock gained 58.8% while the market gained 3.1%) | +55.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 20.6 percentage points (the stock gained 31.7% while the market gained 11.1%) | +20.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 11.7 percentage points (the stock gained 32.2% while the market gained 20.5%) | +11.7% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 13.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 9% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $9.80 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +9.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $11.00 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -2.6% |
Price levels it has turned at before
RGNX last closed at $10.72 on 2026-08-21. Since 2024-08-21 it has turned at 12 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $10.79 | Resistance | 0.7% above the last close | turned there twice · 2025-11-07 to 2026-03-10 |
| $10.58 | Support | 1.3% below the last close | turned there five times · 2024-12-09 to 2025-11-18 |
| $11.04 | Resistance | 3.0% above the last close | turned there twice · 2024-09-05 to 2025-06-02 |
| $11.29 | Resistance | 5.4% above the last close | turned there twice · 2024-10-21 to 2026-05-11 |
| $9.28 | Support | 13.4% below the last close | turned there three times · 2025-07-10 to 2025-08-14 |
| $9.09 | Support | 15.3% below the last close | turned there four times · 2024-10-10 to 2026-07-28 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $11.50.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 4 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Broke out to a new 20-day high · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.64 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$24.55 range $10.00 – $50.00; median $20.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for RGNX
- Consensus EPS estimate-$1.27 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Regulatory approval risk: Company faces a Complete Response Letter for RGX-121 and clinical holds for RGX-111 and RGX-121, requiring resolution with FDA before advancement","Dependence on development partnerships with AbbVie and Nippon Shinyaku; loss of these collaborations would significantly impact pipeline and commercialization prospects","Substantial cash burn and going concern: Company is unprofitable with negative net margin of -330.23% and declining revenue; requires additional financing to continue operations and fund clinical trials"]
What changed in the latest 10-Q
AI-assisted comparison of RGNX's 10-Q filed 2026-05-14 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Annual Report on Form 10-K for year ended December 31, 2025, filed March 5, 2026 (vs. older filing references year ended December 31, 2024, filed March 13, 2025)
- Newer filing states sura-vec enrollment has been completed in AAVIATE trial
- Newer filing specifies NAAVIGATE is a two-part study with Phase IIb portion and Phase III expansion including part two of U.S. trial and parallel global trial led by AbbVie
- Newer filing states first patient dosing in NAAVIGATE expected in second quarter of 2026 with entitlement to $100.0 million milestone payment from AbbVie
- Newer filing reports Phase I/II results for RGX-202 reported between November 2024 and March 2026
- Newer filing reports RGX-202 Phase I/II had no serious adverse events or adverse events of special interest among all patients (n=13)
- Newer filing reports all pivotal dose RGX-202 patients exceeded 10% microdystrophin expression
- Newer filing reports five participants in RGX-202 Phase I/II exceeded expected disease trajectory on NSAA at one year (text truncated)
- Newer filing specifies AFFINITY DUCHENNE is for ambulatory patients aged 1 to 11 years old
- Removed:
- Older filing described sura-vec development with bullet point format listing multiple trial details
- Older filing stated AAVIATE 'continues to enroll a new cohort' at dose level 4 (indicating ongoing enrollment vs. completed)
- Older filing included historical January 2024 AAVIATE data regarding 106 patients, 80% reduction in annualized injection rate, and 50% injection-free outcomes
- Older filing included detailed safety specifics from July 29, 2024 such as episcleritis in three patients and absence of specific complications (endophthalmitis, vasculitis, etc.)
- Older filing stated 'Site selection for the Phase IIb/III trial is in progress' (vs. newer states enrollment initiated)
- Older filing included information about DME cohort in ALTITUDE with enrollment completed in June 2025
- Older filing stated RGX-202 trial designed to enroll approximately 30 patients in U.S. and Canada
- Older filing described AFFINITY DUCHENNE as evaluating patients aged 'one and older' (vs. newer specifies '1 to 11 years old')
- Reworded:
- Newer filing uses subsection heading 'Sura-vec for Treatment of Wet AMD' vs. older uses 'Wet AMD'
- Newer filing uses subsection heading 'Sura-vec for Treatment of DR and DME' vs. older uses 'DR and DME'
- Newer filing states sura-vec 'currently being evaluated' vs. older states ABBV-RGX-314 'is currently being evaluated'
- Newer filing states enrollment completed in ATMOSPHERE and ASCENT in October 2025 with topline data expected Q4 2026 'in partnership with AbbVie' (added phrase)
- Newer filing refers to 'sura-vec' consistently vs. older filing used both 'ABBV-RGX-314' and 'sura-vec'
- Newer filing describes ALTITUDE data as from August 2025 showing positive 2-year data vs. older describes August 2025 announcement of new data and planned pivotal program
- Newer filing states 'we and AbbVie announced an amendment to our collaboration agreement and plans to initiate' vs. older states 'we and AbbVie executed an amendment to our collaboration agreement and announced plans'
- Newer filing characterizes NAAVIGATE as 'two-part, multicenter, randomized, masked, sham-controlled Phase IIb/III study' vs. older states 'two-part sham injection-controlled Phase IIb/III trial'
- Newer filing specifies primary endpoint as '> 2-step improvement on the DRSS' vs. older uses '≥2-step DRSS improvement'
- Notes:
- Older filing text appears truncated at end of RGX-202 section; newer filing text also truncated at RGX-202 section end, limiting full comparison of that program's changes
- Comparison is between Q1 2026 filing (newer) and Q3 2025 filing (older), spanning approximately 6 months of clinical development
Risk Factors
- Added:
- Newer filing adds: 'our ability to address the deficiencies cited in the Complete Response Letter for RGX‑121' as a forward-looking statement risk factor (filed 2026-05-14)
- Newer filing adds: 'our ability to resolve the partial clinical hold for RGX‑111 to the satisfaction of the FDA' as a forward-looking statement risk factor (filed 2026-05-14)
- Newer filing adds 'NAAVIGATE' to the list of clinical trials mentioned (filed 2026-05-14)
- Newer filing adds 'our ability to continue as a going concern' as a forward-looking statement risk factor (filed 2026-05-14)
- Removed:
- Older filing included 'ASCENT' with a registered trademark symbol (®); newer filing removes the ® symbol from ASCENT in the clinical trials list (filed 2025-11-06 vs 2026-05-14)
- Reworded:
- Newer filing: 'our ability to obtain, including under accelerated approval, and maintain regulatory approval' vs older filing: 'our ability to obtain and maintain regulatory approval' - adds reference to accelerated approval (filed 2026-05-14)
- Newer filing changes product description from 'ABBV-RGX-314' to 'surabgene lomparvovec (sura-vec, ABBV-RGX-314)' with trade name and abbreviation (filed 2026-05-14)
- Newer filing changes 'RGX-121 and RGX-111' to 'RGX-121 (clemidsogene lanparvovec) and RGX-111' - adds generic names (filed 2026-05-14)
- Newer filing changes 'Nippon Shinyaku' to 'Nippon Shinyaku Co., Ltd.' (filed 2026-05-14)
- Older filing references 'Annual Report on Form 10-K for the year ended December 31, 2024'; newer filing references 'Annual Report on Form 10-K for the year ended December 31, 2025' (filed 2025-11-06 vs 2026-05-14)
- Older filing line item page numbers (Item 1A through Item 6 at pages 46-47); newer filing shows different page numbers (40-41) (filed 2025-11-06 vs 2026-05-14)
- Notes:
- The provided text sections from both filings end mid-document; only the forward-looking statements and available information sections are fully comparable
- Page number changes reflect document structure differences between the two quarterly reports but do not necessarily indicate substantive content changes
- ASCENT trademark symbol change may be a formatting variation rather than a substantive revision
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 3 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 3 sells ($718232) — 1 selling insider
- Last 180 days0 buys · 4 sells ($886937) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-02. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about RGNX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding RGNX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 9,168,147
- Reported value $76,829,068
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
RGNX had 7,194,939 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
RGNX had 10.9% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.79 days to cover at the same settlement.
- Reported short interest (shares) 7,194,939
- Short interest (% of shares outstanding) 10.9%
- Prior settlement (shares) 8,626,772
- Reported change -16.6%
- Days to cover (reported) 3.79
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Spark Therapeutics (Roche)
- Bluebird Bio (BLUE)
- Sarepta Therapeutics (SRPT)
- UniQure (QURE)
- Beam Therapeutics (BEAM)
- Editas Medicine (EDIT)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare RGNX vs…
Frequently asked questions
What does REGENXBIO INC (RGNX) do?
RegenxBio Inc. is a clinical-stage gene therapy company developing treatments for inherited retinal diseases, hemophilia B, and other genetic disorders. The company employs adeno-associated virus (AAV) vectors as its core technology platform to deliver therapeutic genes to target tissues. Key programs include collaborations with AbbVie for surabgene lomparvovec (ABBV-RGX-314) and with Nippon Shinyaku for RGX-121 and RGX-111, alongside an internal pipeline of investigational therapies in…
What sector is REGENXBIO INC (RGNX) in?
REGENXBIO INC (RGNX) is classified in the Health Care sector. Its industry is Biotechnology - Gene Therapy. It trades on NASDAQ.
Who are REGENXBIO INC's (RGNX) competitors?
Notable peers of REGENXBIO INC (RGNX) include Spark Therapeutics (Roche), Bluebird Bio, Sarepta Therapeutics, UniQure and Beam Therapeutics. This peer set is informational only — not financial advice.
Is REGENXBIO INC (RGNX) overbought or oversold right now?
REGENXBIO INC (RGNX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 49, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RGNX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.